arrow
M

Matthäus Felsenstein

cliniques universitaires saint-luc
H指数:14
被引数:876

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma

R0切除可改善胰腺导管腺癌多脏器切除后的生存率

2026-09-010
OAAI
The basis for future personalized therapy approaches-Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pancreatic cancer patients

未来个性化治疗方案的依据—机器学习生成的胰腺癌患者1年生存率、转移状态和治疗依赖性生存

2025-12-012
OAAI
GerPaCyst - The trial protocol of the prospective, multicenter, interdisciplinary German Pancreas Club Cyst Registry

GerPaCyst - 该前瞻性、多中心、跨学科德国胰腺俱乐部囊肿登记研究的试验方案

2025-11-251
PRE
Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids

多药药理学分型改善了胰腺癌类器官的治疗预测

2025-09-180
OAAI
Endoscopic versus percutaneous drainage placement after left-sided pancreatectomy: Multi-state model for defining objectifiable variables on interventional treatment for pancreatic fistula.

内镜引流与经皮引流置管在左胰腺切除术后:用于定义胰腺瘘介入治疗中可客观化变量的多状态模型。

HPB
IF2.4
2025-07-050
PREAI
Extracellular NAD+ levels are associated with CD203a expression on Th17 cells and predict long-term recurrence-free survival in hepatocellular carcinoma

细胞外NAD+水平与Th17细胞上CD203a的表达相关,并能预测肝细胞癌的长期无复发生存率。

2025-03-190
OA
Cytokine-armed vaccinia virus promotes cytotoxicity toward pancreatic carcinoma cells via activation of human intermediary CD56dimCD16dim natural killer cells
2024-10-141
OA
Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?

胰腺导管腺癌 (PDAC) 的神经周围浸润: 治愈性治疗的破坏者?

2022-04-2320
OAAI
Sensing Acute Cellular Rejection in Liver Transplant Patients Using Liver-Derived Extracellular Particles: A Prospective, Observational Study
2021-05-054
OAAI
Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct

胰腺和胆管的导管内嗜酸细胞性乳头状肿瘤中PRKACA和PRKACB的复发性重排

2020-02-01111
OAAI